세계의 연조직 복구 시장 보고서 : 제품, 용도, 최종 용도, 지역별(2024-2032년)

The global soft tissue repair market size reached US$ 14.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 19.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032.

Soft tissues comprise muscles, tendons, fascia, nerves, fat, ligaments, blood vessels, and synovial membranes that connect, surround, and support other structures and organs of the body. Many physical activities can lead to their damage, which further results in pain, sprains, strains, swelling, bursitis, tendinitis, and contusions. As a result, various remedial interventions are utilized for restoring, repairing, and regenerating soft tissues. For instance, scaffolds made using natural polymers like chitosan, gelatin, and alginate are used as biomaterials for their repair. Besides this, the use of allografts and xenografts is also gaining traction for repairing severe damages around the world.

Soft Tissue Repair Market Trends:

The growing participation of individuals, especially children, in professional sports increases the risk of developing an injury in soft tissues. This, in confluence with the increasing concerns among parents about the physical health of their child, represents one of the primary factors influencing the market growth positively. Its repair helps in faster recovery and improving athletic performance. Apart from this, the growing aging population is catalyzing the demand for biomaterials that have high efficiency and can effectively repair damaged soft tissues in a short time. These biomaterials are also used in a variety of soft tissue procedures, including dural tears, chest wall reconstruction, cardiac and cardiovascular surgery, abdominal wall repair, and pelvic organ prolapse treatment. Furthermore, rising incidences of musculoskeletal disorders is promoting the need for biomedical implants to reorganize the bone and its associated soft tissues. Other factors, such as favorable reimbursement policies, the increasing popularity of medical tourism, and rising investments in research and development (R&D) activities, are anticipated to strengthen the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global soft tissue repair market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end use.

Breakup by Product:

Fixation Products

Suture

Suture Anchors

Tissue Patch/Match

Biological

Synthetic

Breakup by Application:

Orthopedic Surgery

Breast Reconstruction

Hernia Repair

Skin Repair

Vaginal Sling Repair

Cardiovascular Surgery

Others

Breakup by End Use:

Hospitals and Clinics

Research and Academic Institutes

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Arthrex Inc., Becton Dickinson and Company, Baxter International Inc., Cryolife Inc., Integra LifeSciences Corporation, Johnson & Johnson, Medtronic Plc, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation and Terumo Corporation.

Key Questions Answered in This Report

• 1. How big is the global soft tissue repair market?
• 2. What is the expected growth rate of the global soft tissue repair market during 2024-2032?
• 3. What are the key factors driving the global soft tissue repair market?
• 4. What has been the impact of COVID-19 on the global soft tissue repair market?
• 5. What is the breakup of the global soft tissue repair market based on the product?
• 6. What is the breakup of the global soft tissue repair market based on the application?
• 7. What is the breakup of the global soft tissue repair market based on the end use?
• 8. What are the key regions in the global soft tissue repair market?
• 9. Who are the key players/companies in the global soft tissue repair market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Soft Tissue Repair Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Fixation Products
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Suture
    • 6.1.2.2 Suture Anchors
  • 6.1.3 Market Forecast
• 6.2 Tissue Patch/Match
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Biological
    • 6.2.2.2 Synthetic
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Orthopedic Surgery
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Breast Reconstruction
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Hernia Repair
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Skin Repair
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Vaginal Sling Repair
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Cardiovascular Surgery
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research and Academic Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Arthrex Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Becton, Dickinson and Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Baxter International Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Cryolife Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Integra LifeSciences Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Johnson & Johnson
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Medtronic Plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Organogenesis Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Smith & Nephew plc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Stryker Corporation
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Terumo Corporation
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis